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Abstract
Background Doxorubicin (Dox) is one of the most potent
anticancer drugs, but its successful use is hampered by high
toxicity caused mainly by generation of reactive oxygen
species. One approach to protect against Dox-dependent
chemical insult is combined use of the cytostatic drug with
antioxidants. C60 fullerene has a nanostructure with both
antioxidant and antitumor potential and may be useful in
modulating cell responses to Dox.
Objective The aim of this study was to estimate the
antitumor effect and antioxidant enzyme activity of com-
bined C60 fullerene and Dox (C60 ? Dox) in the liver and
heart of mice with Lewis lung carcinoma compared with
Dox treatment alone.
Methods Highly stable pristine C60 fullerene aqueous
colloid solution (concentration 1.0 mg/ml, average hydro-
dynamic diameter of nanoparticles 50 nm) was used in the
study and characterized by means of atomic force
microscopy (AFM). The in vivo investigation of C60-Dox
action was performed via the standard methods of histo-
logical and enzyme activity analyses.
Results Dox (total dose 2.5 mg/kg) combined with C60
fullerene (total dose 25 mg/kg) in tumor-bearing animals
resulted in tumor growth inhibition, prolongation of life,
metastasis inhibition, and increased number of apoptotic
tumor cells and was more effective than the corresponding
course of Dox treatment alone. C60 fullerene demonstrated
a protective effect against superoxide dismutase and glu-
tathione peroxidase inhibition induced by Dox-dependent
oxidative insult in the liver and heart.
Conclusion Combined treatment with C60 ? Dox is
considered to be a promising approach for cancer
chemotherapy.
Key Points
C60 fullerene protects the heart and liver of tumor-
bearing animals against doxorubicin (Dox)-induced
oxidative stress.
Combined antitumor treatment of C60 fullerene and
Dox is more effective than Dox treatment alone.
1 Introduction
Oncological diseases, particularly lung cancer, breast can-
cer, and leucosis, are common and carry a high mortality
rate. Several cytostatic drugs, including doxorubicin (Dox),
are used in the therapy of malignant tumors. Dox is an
antibiotic of the anthracycline group, with a wide range of
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clinical activity against solid tumors and hemoblastoses,
lung carcinoma, and acute leukemia [1]. Dox non-cova-
lently binds to DNA, blocking the synthesis of nucleic
acids, and demonstrates high antimitotic activity and pro-
nounced mutagenic effect, but exerts toxic effects in nor-
mal tissues and cells [2].
One approach to protect against Dox-induced chemical
insult to normal tissues is a combined use of the cytostatic
drug with antioxidants of a different nature [3]. C60 ful-
lerene has recently been recognized as a promising agent
for use in anticancer therapy [4, 5]. C60 fullerene and its
derivatives are biocompatible, show no toxic effects on
normal tissues at low concentrations, possess strong free-
radical-scavenging and antioxidant potential [6–10], and
demonstrate a protective effect against Dox-induced
chronic cardio- and hepatotoxicity [11]. The tumor-
inhibitory activity of nanoparticles containing C60 fuller-
ene has been studied in models of murine hepatocarci-
noma [12] and rat colorectal cancer and mammary
carcinoma [3, 13, 14]. Finally, recent results indicate that
C60 fullerene complexation with Dox may be a key pro-
cess leading to alteration of the antitumor effect of Dox
in vitro [15, 16].
The study of the biological effects of pristine C60 ful-
lerene is limited by its hydrophobicity, difficulties involved
with reaching sufficient concentration, and aggregation in
water [17]. For this reason, hydrophilic derivatives
obtained by chemical modification of the C60 fullerene
outer surface were used in most studies of C60 fullerene
antioxidant and antineoplastic effects [10, 12, 18]. How-
ever, derivatization does not completely prevent cluster
formation. Moreover, substantial modification of the C60
fullerene core appears to cause a perturbation of the p-
conjugated electronic system of cyclohexatriene units on
the molecular surface and hence may influence C60 ful-
lerene reactivity [19, 20]. The use of a stable water colloid
dispersion of pristine C60 fullerene has shown promise for
the comprehensive analysis of C60 fullerene biological
effects and antitumor efficiency [21].
The aim of this study was to estimate the antitumor
effect and antioxidant enzyme activity in the liver and heart
of mice with Lewis lung carcinoma (LLC) after combined
treatment with C60 fullerene and Dox as compared with
treatment with Dox alone.
2 Materials and Methods
2.1 Chemicals
Dox (Ebewe, Austria), paraformaldehyde, paraplast
(Richard-Allan Scientific, USA), DC Protein (Bio-Rad,
USA), superoxide dismutase (SOD), and glutathione
peroxidase (GP) assay kits were purchased from Fluka
(Buchs, Switzerland) and Sigma-Aldrich (Saint Louis,
USA).
2.2 Preparation of Pristine C60 Fullerene Water Colloid
Solution
The C60 fullerene powder with a purity of [99.8 % was
prepared according to a published protocol [22]. The highly
stable and reproducible pristine C60 fullerene aqueous
colloid solution (C60FAS; concentration 1.0 mg/ml, purity
[99.5 %) was prepared, as published previously [23], by
the transfer of C60 fullerene molecules from toluene to an
aqueous phase with the help of ultrasonic treatment.
2.3 Atomic Force Microscopy Characterization of C60
Fullerene Aqueous Colloid Solution
The state of C60 fullerene in aqueous solution was monitored
using atomic force microscopy (AFM; ‘Solver Pro M’ sys-
tem; NT-MDT, Russia). The samples were deposited by
precipitation from an aqueous solution droplet onto cleaved
mica substrate (V-1 Grade, SPI Supplies). Measurements
were performed after complete evaporation of the solvent.
The sample visualization was carried out in semicontact
(tapping) mode with NSG10 (NT-MDT) probes.
2.4 Animals
Male C57Bl/6J mice (20–22 g) were kept at 20 ± 1 C
with free access to standard laboratory diet and water. All
experiments were performed according to the international
principles of the European Convention on protection of
vertebrate animals used for experimental purposes.
2.5 Treatment Protocol
LLC cells (*5 9 105) were subcutaneously inoculated
into the limb of each mouse. The treatment was started on
the 7th day after tumor inoculation when the tumor had
grown up to approximately 5 mm. Tumor-bearing mice
were randomly divided into four groups, with 12 animals
per group.
Mice in the Dox group and the C60 fullerene group
received intraperitoneal (ip) injection of 0.5 mg/kg of Dox
and 5 mg/kg of C60 fullerene, respectively, as a daily dose
for 5 consecutive days with a 1-day interval [4]. Mice in
the C60 ? Dox group received C60FAS ip (dose 5 mg/kg)
20 min before the Dox injection (dose 0.5 mg/kg). The
control cancer group received saline ip only. On the 22nd
day after tumor inoculation (when the first tumor-bearing
animal died in the control cancer group), each group was
randomly divided into two groups; six mice from each
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group were sacrificed and tissues were taken for analysis.
The remaining six mice in each group were used to esti-
mate the lifespan.
2.6 Assay of Antitumor Effects
The antitumor efficiency of the applied technique was
estimated with the following quantitative indexes:
– tumor volume: V ¼ ab2
2
, where a and b are the long and
short diameter of the tumor (mm), respectively [12];
– prolongation of animal life: kp ¼ tetctc  100 %, where
tc and te are the average lifespan (in days) in cancer
control (c) and experimental (e) groups of animals,
respectively [4];
– metastasis inhibition: km ¼ Ac  BcAe  BeAc  Bc  100 %,
where Ac and Ae are the frequency of tumor cell
colonies that have metastasized to the lung; Bc and Be
are the average number of metastases in the lung of
animals in the cancer control (c) and experimental
(e) groups, respectively [4].
2.7 Histological Studies
For histological analysis, tumor tissue was dissected, fixed
in 4 % paraformaldehyde, pH 7.4, dehydrated in ethanol,
embedded at paraplast, and cut into 4 lm slices. After
staining with hematoxylin-eosin (HE), cyto-morphological
characteristics of tumor sections were studied using light
microscopy (Olympus BX51, Japan). The average number
of mitotic (with the specific pattern of chromatin conden-
sation) and apoptotic (with fragmented nucleus and apop-
totic bodies) cells was estimated in sections with the use of
‘Olympus DP-Soft’ morphometric software.
Mitotic or apoptotic indexes were estimated with the
following formula: I ¼ NC
TNC
 100 %, where NC is the
number of mitotic or apoptotic cells, and TNC is the total
number of cells.
2.8 Measurement of Antioxidant Enzyme Activity
The liver and heart were quickly removed from the scari-
fied mice, placed into an ice-cold solution, minced, and
homogenized in 10 mM Tris–HCl, pH 8.0. The samples
were centrifuged at 13,000g for 20 min at 4 C. Superna-
tants were used for the assay of total protein concentration
and spectrophotometric analysis of enzyme activity. Pro-
tein concentration was determined using a DC Protein
Assay Kit.
SOD activity was measured using a competition assay
between SOD and indicator molecule, nitroblue tetrazo-
lium (NBT). One unit of activity was defined as the
concentration of SOD that had inhibited the NBT reduction
rate to half of the maximum. GP activity was estimated in
potassium buffer containing reduced glutathione, NaN3, to
inhibit catalase and H2O2 as the substrate by monitoring
accumulation of glutathione disulfide (GSSG).
2.9 Statistics
Statistical analysis of experimental data was performed
using the Statistica-6.0 computer program (StatSoft Inc.).
Validity of differences between the control and experi-
mental measurements was estimated via the Student’s t-test
(values are given as mean ± standard error; the differences
between the compared values were considered meaningful
at p\ 0.05).
3 Results and Discussion
3.1 Structure of C60 Fullerene Nanoparticles
in Aqueous Colloid Solution
Knowledge of the C60 fullerene aggregation parameters in
aqueous solution is important for estimation of nanostruc-
ture bioactivity and its potential for biomedical application
[18, 24, 25]. An AFM investigation was performed to
characterize the aggregation state of C60 fullerene in
aqueous solution.
The AFM image (Fig. 1) demonstrates that, along with
the individual C60 fullerenes, their bulk aggregates (clus-
ters) with a diameter of up to 50 nm were present on the
mica substrate. These results are in a good agreement with
the data from laser correlation spectroscopy of C60FAS,
which confirm that the average hydrodynamic diameter of
nanoparticles is 50 nm and no further agglomeration is
observed [26]. More detailed analysis of the structural
composition and physico-chemical properties of C60FAS
has been previously accomplished [21, 23] by means of
chemical analysis, ultraviolet-visible spectroscopy (UV/
VIS) and Fourier transform infrared spectroscopy (FTIR),
scanning tunneling microscopy, dynamic light scattering,
and small-angle neutron scattering techniques. In general,
the properties of the C60FAS used in this experiment cor-
respond to those in the published literature data.
3.2 Tumor Growth-Inhibitory Effects
In traditional animal tumor models, Dox is typically
introduced at concentrations of up to 100 mg/kg; however,
high lethality complicates prolonged monitoring of Dox
effects. Injection of the chemotherapeutic agent in lower
doses is more effective than a single injection at an
equivalent dose [2].
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In our experiments, we used a model of multiple ip
injections for a course of Dox treatment with a total dose of
2.5 mg/kg (corresponding to a minimal therapeutic dose),
and in combination with C60 fullerene as a potential anti-
tumor agent and protector against Dox-induced toxicity.
The total dose of C60 fullerene (25 mg/kg) was non-toxic
as expected, since the median lethal dose (LD50) for pris-
tine C60 fullerene ip injected in a water solution to mice
was found to be approximately 600 mg/kg [6].
The kinetics of average tumor volume extension that
manifests the tumor growth was measured in three
experimental groups of animals from the 7th to 22nd day
after tumor inoculation and compared with that of the
control cancer group. The tumor growth inhibition curves
for the various groups are shown in Fig. 2. The tumors
grew the quickest in the control group. Tumor inhibitory
effect in the C60 fullerene-treated group (22.5 %) was
comparable with that in the Dox-treated group (24.2 %).
When C60 fullerene was administered before Dox
(C60 ? Dox group), a stronger inhibitory effect was
observed (36.2 %). Thus, these data indicate that treat-
ment with C60 ? Dox more effectively inhibits tumor
growth than does treatment with Dox or C60 fullerene
separately.
3.3 Quantitative Indexes of Antitumor Effect
Data on the lifespan of the control and treated groups are
presented in Table 1. The last animal in the control cancer
group died on the 30th day of the experiment, whereas the
lifespan of animals in experimental groups was found to be
increased. The last animal in the Dox group died on the
38th day, and those in the C60 fullerene and C60 ? Dox
groups died on the 40th day.
Table 2 shows the quantitative indexes of animal life
prolongation (kp) and metastasis inhibition (km) as the
measure of the total effectiveness of the applied regimes of
antitumor treatment.
LLC cells are highly invasive and quickly spread into
lung tissue and form multiple metastases. Dox treatment
distinctly inhibited tumor dissemination into the lung of
tumor-bearing animals (km * 23 %) but exerted only a
slight effect on life prolongation (kp * 16 %). In the C60
fullerene-treated group, the metastasis inhibition index was
less than that in the Dox-treated group (km * 15 %), but
the life prolongation was greater (kp * 24 %). Both the
anti-metastatic effect (km * 35 %) and the life prolonga-
tion (kp * 32 %) were found to be maximal in the
C60 ? Dox group.
Fig. 1 Atomic force
microscopy image of C60
fullerene nanoparticles
precipitated on mica surface
from C60FAS (0.1 mg/ml)
Fig. 2 Growth inhibition curves for treatment of tumor-bearing
animals with C60 fullerene, doxorubicin, or C60 ? doxorubicin
(p\ 0.05)
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3.4 Cytomorphological Changes in Tumor Tissue
Cytomorphological study of the tumor that developed
subcutaneously in mice in the cancer control group (Fig. 3a)
showed that it consisted of polymorphic cells with a
nucleus, large nucleolus, condensed chromatin, and light
areas of tumor karyoplasm. The high content of mitotic cells
testifies to the proliferative potential of tumor cells. In the
C60 fullerene-treated group, the tumor mitotic index did not
change, but the apoptotic index was found to be higher than
in the control cancer group (Figs. 3b and 4). Dox treatment
was followed by a reduction in the number of mitotic cells
and an increase in the number of apoptotic cells, i.e. by
inhibition of proliferative potential and induction of tumor
cell death (Figs. 3c, 4). When the tumor-bearing animals
were exposed to treatment with C60 ? Dox, the number of
apoptotic cells substantially increased and zones containing
apoptotic, necrotic cells and infiltrating macrophages were
detected (Figs. 3d and 4).
3.5 Activity of Antioxidant Enzymes in Liver
and Heart
Dox chemotherapy is known to be accompanied by the
generation of reactive oxygen species (ROS) and
immediate oxidative damage of cells with high oxidative
metabolism and activity of mitochondrial respiratory chain,
particularly cardiac myocytes and hepatocytes. SOD and
GP are the predominant antioxidant enzymes. The first step
of antioxidant defense is the dismutation of superoxide
anion into hydrogen peroxide by inducible SOD; the sec-
ond is conversion of hydrogen peroxide to water by GP.
The activity of SOD and GP was estimated in the liver and
heart of animals in the cancer control, Dox-, and
C60 ? Dox-treated groups. No reliable difference in the
level of heart and liver antioxidant enzymes in the C60
fullerene group as compared with the cancer control group
was observed.
Prolonged Dox administration resulted in a decrease of
SOD as well as of GP activities in both mice liver and mice
heart (Fig. 5). Since activity of both enzymes is known to
undergo feedback inhibition by excessive levels of perox-
ides and lipoperoxides, it could be that Dox-dependent
oxidative stress diminishes ROS-scavenging activity of
SOD and GP in the liver and heart of tumor-bearing
animals.
No inhibition of antioxidant enzyme activity was
detected in the C60 ? Dox-treated group; the level became
comparable with that in the control group (SOD activity in
liver and heart and GP activity in heart) or even exceeded
that in the control group (GP in liver) (Fig. 5). This
favorable phenomenon is likely to be associated with the
ability of C60 fullerene to function as a ROS scavenger or
SOD mimetic [27] and to decrease the production of ROS
to the optimal level for antioxidant enzyme activation. Up-
regulation of SOD has previously been shown to enhance
cell survival in the presence of Dox through its role as a
free radical scavenger [28]. In addition, overexpression of
cytosolic and mitochondrial GP appeared to protect mice
hearts against Dox-induced cardiotoxicity and to prevent
impairment of mitochondrial respiration and inhibition of
complex I activity [29].
This study has shown that the treatment of tumor-bear-
ing mice with ip injection of C60 ? Dox from the 7th day
after LLC cell inoculation resulted in tumor growth slow-
down, metastasis inhibition, and lifespan prolongation.
These indexes were also increased after Dox or C60 ful-
lerene were administered as single agents, but the antitu-
mor effect was most pronounced in the C60 ? Dox group.
The histological analysis of tumor tissue in the C60 ? Dox-
treated group confirmed the inhibition of proliferating
tumor cells, induction of apoptotic and necrotic cell death,
and macrophage infiltration.
In several previous in vitro studies, internalization of
pristine C60 fullerene into cancer cells was demonstrated,
but no cytotoxic effects were observed. When human lung
carcinoma A549 cells were exposed to pristine C60 ful-
lerene dispersion (particle size 100–200 nm), internalized
Table 1 Lifespan of animals in different groups
Days after tumor
inoculation
Treatment group (n)
Cancer
control
Doxorubicin C60
fullerene
C60 ?
doxorubicin
22 6 6 6 6
24 2 5 5 5
26 1 2 4
28 3
30 0 3
32 2
34 1
36 1
38 0 1
40 0 0
Table 2 Indexes of metastasis inhibition (km) and animal life pro-
longation (kp) in groups of treated tumor-bearing mice
Treatment km, % kp, %
Doxorubicin 23 ± 4* 16 ± 4
C60 fullerene 15 ± 2 24 ± 4*
C60 ? doxorubicin 35 ± 5* 32 ± 5*
* p\ 0.05 compared with the cancer control group (untreated
animals)
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C60 fullerene aggregates were detected in the cytoplasm
and lysosomes. Neither apoptosis nor necrosis was
induced, while cell proliferation was inhibited [30].
Malignant breast epithelial cells were shown to take up
pristine C60 fullerene from methanol C60 fullerene solution
(particle size 106–342 nm), and the treatment of these cells
with C60 fullerene up to 200 lg/ml did not alter the mor-
phology, cytoskeleton organization, cell cycle dynamics, or
cell proliferation [31].
Other studies on pristine C60 fullerene distribution in
animal tissues after ip administration demonstrated nano-
particle uptake into the circulation, accumulation in the
liver at 120 min post-exposure, and nearly complete
elimination by day 13, with minimal accumulation in the
spleen, lung, and muscle [6, 32].
Fig. 3 Histological sections of hematoxylin–eosin-stained tumor tissue (magnification 9 400): (a) cancer control group, (b) C60 fullerene group,
(c) doxorubicin group, (d) C60 ? doxorubicin group. A apoptosis, M mitosis, N necrosis, *indicates macrophage
Fig. 4 Tumor mitotic and apoptotic indexes in groups of treated
tumor-bearing mice. *p\ 0.05 vs. the cancer control group
(untreated animals). C60 C60 fullerene, Dox doxorubicin
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Internalization of C60 fullerene in tumor tissue has also
been demonstrated with in vivo models and different water-
soluble C60 fullerene derivatives. In a mouse model of liver
cancer, malonodiserinolamide-derivatized C60 fullerene
nanoparticles were detected permeating through the altered
vasculature of the tumor, evading the reticulo-endothelial
system [33]. Gd@C82(OH)22 nanoparticles administered ip
at a dose level of approximately 10-7 mol/kg were shown to
exhibit high antineoplastic activity against murine H22
hepatocarcinoma, but only 0.05 % of the exposed dose
reached the tumor tissue [34]. It was also demonstrated that
fullerol C60(OH)x nanoparticles were mainly taken up by the
mononuclear phagocyte system, and only 0.2 % were
accumulated in the murine H22 hepatocarcinoma within
24 h due to enhanced permeability and retention effects [35].
Nevertheless, C60(OH)x in doses of 0.2 and 1 mg/kg was
found to exhibit significant tumor-inhibitory activity [12].
Considering that no marked accumulation of C60 ful-
lerene was detected in tumors and no direct toxic effect on
tumor cells was observed, it is assumed that antitumor
efficiency of C60 fullerene derivatives is not due to the
direct killing of tumor cells but is the result of tumor
microenvironment regulation and/or immune response
activation [12, 36–38]. On the other hand, our finding of
C60 fullerene-dependent enhancement of Dox antitumor
effect does not exclude the possibility that C60 fullerene
nanoparticles promote Dox accumulation in tumor cells by
activating drug endocytosis, as it was shown for
Gd@C82(OH)22 nanoparticles that may restore defective
endocytosis of cisplatin by cancer cells [39].
The most severe side effect of Dox treatment is free
radical-mediated damage to liver and heart tissue, which
are very sensitive to free radical damage because of their
high oxidative metabolism. In this study, we have dem-
onstrated a beneficial effect of pristine C60 fullerene in a
low-dose regime (5 mg/kg) on heart and liver antioxidant
defense against Dox treatment in tumor-bearing mice. The
greater protective effect of lower doses of fullerols (25 mg/
kg) in contrast to higher doses (50 and 100 mg/kg) against
Dox-associated toxicity was confirmed for rat hearts and
livers with colorectal cancer [3, 40]. This observation is
likely to be associated with the fact that the higher doses
were less well absorbed from the peritoneal cavity.
In summary, we can conclude that pristine C60 fullerene
exhibits health effects and antitumor activity in combined
treatment with Dox. These results need to be investigated
further in a number of tumor models.
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